caffeine has been researched along with melphalan in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (26.32) | 18.7374 |
| 1990's | 2 (10.53) | 18.2507 |
| 2000's | 8 (42.11) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Andricopulo, AD; Moda, TL; Montanari, CA | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Merriman, RL; Sladek, NE | 1 |
| Dozi-Vassiliades, J; Granitsas, A; Mourelatos, D; Myrtsiotis, A | 1 |
| Brown, DM; Brown, JM; Hirst, DG; Horsman, MR | 1 |
| Parsons, PG | 1 |
| Byfield, JE; Calabro-Jones, P; Kulhanian, F; Lynch, M; Murnane, J; Ward, JF | 1 |
| Adams, EG; Bhuyan, BK; Folz, BA; Smith, KS | 1 |
| Lialiaris, TS; Pantazaki, AA | 1 |
| Bozko, P; Larsen, AK; Sabisz, M; Skladanowski, A | 1 |
| Cerboni, C; Cippitelli, M; Di Gialleonardo, V; Fionda, C; Foà, R; Guarini, A; Iannitto, ML; Petrucci, MT; Ricciardi, MR; Santoni, A; Soriani, A; Zingoni, A | 1 |
1 review(s) available for caffeine and melphalan
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
18 other study(ies) available for caffeine and melphalan
| Article | Year |
|---|---|
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Hologram QSAR model for the prediction of human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Holography; Humans; Models, Biological; Models, Molecular; Molecular Structure; Pharmaceutical Preparations; Pharmacokinetics; Quantitative Structure-Activity Relationship | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Cytotoxic activity of mechlorethamine and melphalan against cultured tumor cells: potentiation by caffeine.
Topics: Animals; Antineoplastic Agents; Caffeine; Carcinoma 256, Walker; Cells, Cultured; Drug Synergism; Lymphoma; Mechlorethamine; Melphalan; Rats; Time Factors | 1978 |
Induction of sister-chromatid exchanges and cell-cycle delays in human lymphocytes by vitamin A alone or in combination with melphalan and caffeine.
Topics: Caffeine; Cells, Cultured; Drug Synergism; Humans; Lymphocytes; Melphalan; Mitosis; Mitotic Index; Sister Chromatid Exchange; Vitamin A | 1985 |
Enhancement of melphalan cytotoxicity in vivo and in vitro by inhibitors of poly (ADP-ribose) polymerase.
Topics: Animals; Benzamides; Caffeine; Cell Line; Cell Survival; Cricetinae; Cricetulus; Dose-Response Relationship, Drug; Drug Synergism; Drug Therapy, Combination; Female; Melphalan; Mice; Mice, Inbred C3H; NAD+ Nucleosidase; Neoplasm Transplantation; Neoplasms, Experimental; Niacinamide; Poly(ADP-ribose) Polymerase Inhibitors; Time Factors | 1984 |
Dependence on treatment time of melphalan resistance and DNA cross-linking in human melanoma cell lines.
Topics: Caffeine; Cell Line; Cell Survival; Chlorambucil; DNA, Neoplasm; Drug Resistance; Drug Synergism; Hot Temperature; Humans; Kinetics; Mechlorethamine; Melanoma; Melphalan; Methyl Methanesulfonate; Thymidine | 1984 |
Mice, men, mustard and methylated xanthines: the potential role of caffeine and related drugs in the sensitization of human tumours to alkylating agents.
Topics: Alkylating Agents; Animals; Caffeine; Cell Survival; Cells, Cultured; Cyclophosphamide; DNA Repair; DNA Replication; DNA, Neoplasm; HeLa Cells; Humans; Melphalan; Mice; Neoplasms, Experimental; Rats; Ultraviolet Rays; Xanthines | 1981 |
Synergistic and additive combinations of several antitumor drugs and other agents with the potent alkylating agent adozelesin.
Topics: Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Aphidicolin; Azacitidine; Benzofurans; Caffeine; Cell Survival; CHO Cells; Cisplatin; Cricetinae; Cricetulus; Cyclohexanecarboxylic Acids; Cyclohexenes; Decitabine; Deoxyadenosines; DNA; Dose-Response Relationship, Drug; Drug Synergism; Duocarmycins; Indoles; Melanoma, Experimental; Melphalan; Mutagens; Organoplatinum Compounds; Pentoxifylline; Tumor Cells, Cultured | 1995 |
A combined biochemical and cytogenetic study of thioridazine-induced damage to nucleic acids.
Topics: Caffeine; Cells, Cultured; Deoxyribonuclease BamHI; DNA Restriction Enzymes; Humans; Lymphocytes; Melphalan; Mutagenicity Tests; Nucleic Acids; Sister Chromatid Exchange; Thioridazine | 1999 |
Cross-talk between DNA damage and cell survival checkpoints during G2 and mitosis: pharmacologic implications.
Topics: Antineoplastic Agents, Alkylating; Blotting, Western; Caffeine; Cell Line; Cell Survival; DNA Damage; DNA Fragmentation; G2 Phase; Humans; Melphalan; Mitosis; Nocodazole; Paclitaxel; Signal Transduction | 2005 |
ATM-ATR-dependent up-regulation of DNAM-1 and NKG2D ligands on multiple myeloma cells by therapeutic agents results in enhanced NK-cell susceptibility and is associated with a senescent phenotype.
Topics: Antibiotics, Antineoplastic; Antigens, Differentiation, T-Lymphocyte; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Ataxia Telangiectasia Mutated Proteins; Caffeine; Cell Cycle Proteins; Cell Degranulation; Cell Line, Tumor; Cellular Senescence; DNA-Binding Proteins; Doxorubicin; GPI-Linked Proteins; Humans; Intercellular Signaling Peptides and Proteins; Killer Cells, Natural; Melphalan; Morpholines; Multiple Myeloma; Phosphodiesterase Inhibitors; Protein Serine-Threonine Kinases; Pyrones; Tumor Suppressor Proteins; Up-Regulation | 2009 |